ERBB2 and breast cancer: For example, a study assessing the correlation of HER2 expression between primary tumours and corresponding circulating tumour cells in human advanced breast cancer patients found non-concordant results in 32% of cases (i.e., patients with HER2-negative primary tumours had HER2-positive CTCs and vice versa) [254].